Evaluating and mitigating clinical samples matrix effects on TX-TL cell-free performance

Cell-free biosensors are promising tools for medical diagnostics, yet their performance can be affected by matrix effects arising from the sample itself or from external components. Here we systematically evaluate the performance and robustness of cell-free systems in serum, plasma, urine, and saliva using two reporter systems, sfGFP and luciferase. In all cases, clinical samples have a strong inhibitory effect. Of the different inhibitors, only RNase inhibitor mitigated matrix effects. However, we found that the recovery potential of RNase inhibitor was partially muted by interference from glycerol contained in the commercial buffer. We solved this issue by designing a strain producing an RNase inhibitor protein requiring no additional step in extract preparation. Furthermore, our new extract yielded higher reporter levels than previous conditions and tempered interpatient variability associated with matrix effects. This systematic evaluation and improvements of cell-free system robustness unified across many types of clinical samples is a significant step towards developing cell-free diagnostics for a wide range of conditions.

Automated summary

Cell-free biosensors are promising tools for medical diagnostics, but their performance can be affected by matrix effects. This study systematically evaluated the performance and robustness of cell-free systems in different clinical samples and found that an RNase inhibitor can mitigate matrix effects. By designing a new strain, interference from glycerol in the commercial buffer was resolved and higher reporter levels were obtained.